Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Areata Alopecia Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

NCT04797650
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543 matching placebo, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

NCT02312882
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Tofacitinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Long-Term PF-06651600 for the Treatment of Alopecia Areata

NCT04006457
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Not listed No phase listed Observational

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

NCT05084417
View directory record Official record
Conditions
Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions
N/A This is an observational study
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jun 11, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

NCT07029828
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib higher dose, Ritlecitinib lower dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 14 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Encinitas, California • Miami, Florida • Tamarac, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Completed No phase listed Observational

A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

NCT07200128
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Childhood Alopecia Areata Study Using the 308-nm Excimer Laser

NCT01736007
View directory record Official record
Conditions
Alopecia Areata
Interventions
308-nm excimer laser to alopecia patch, Liquid light guide tip on laser
Device
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jun 11, 2026, 5:09 AM EDT
Recruiting Phase 1 Interventional

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

NCT07049328
View directory record Official record
Conditions
Alopecia Areata(AA)
Interventions
HCW9302, an IL-2 fusion protein
Drug
Lead sponsor
HCW Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

NCT00484679
View directory record Official record
Conditions
Alopecia Areata
Interventions
Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jun 11, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198
View directory record Official record
Conditions
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
44
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240
View directory record Official record
Conditions
Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 63 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
75
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Vitamin D in Subjects With Alopecia Areata

NCT01328678
View directory record Official record
Conditions
Alopecia Areata
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

NCT05368103
View directory record Official record
Conditions
Alopecia Areata
Interventions
Daxdilimab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Hot Springs, Arkansas • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Tofacitnib for the Treatment of Alopecia Areata and Variants

NCT02197455
View directory record Official record
Conditions
Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)
Interventions
Tofacitinib Administration
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 11, 2026, 5:09 AM EDT
Recruiting No phase listed Observational

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Montgomery, Alabama • Fremont, California • Fresno, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

NCT02553330
View directory record Official record
Conditions
Alopecia Areata
Interventions
Placebo Cream, Ruxolitinib Phosphate Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

A Phase II Study in Patients With Alopecia Areata

NCT04346316
View directory record Official record
Conditions
Alopecia Areata
Interventions
SHR0302
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Northridge, California • Brandon, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata

NCT00063076
View directory record Official record
Conditions
Alopecia Areata
Interventions
Targretin Gel 1%
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jun 11, 2026, 5:09 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias

NCT06357169
View directory record Official record
Conditions
Lichen Planopilaris of Scalp, Alopecia Areata
Interventions
Venus Glow
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alefacept in Patients With Severe Scalp Alopecia Areata

NCT00167102
View directory record Official record
Conditions
Alopecia Areata
Interventions
Alefacept
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Jun 11, 2026, 5:09 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 11, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Secukinumab for the Treatment of Alopecia Areata

NCT02599129
View directory record Official record
Conditions
Alopecia Areata
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jun 11, 2026, 5:09 AM EDT
Not listed Not applicable Interventional

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata

NCT03078686
View directory record Official record
Conditions
Alopecia Areata, Scarring Alopecia
Interventions
tSVF by lipoaspiration, PRP Concentration, Emulsification tSVF, cSVF isolation and concentration, cSVF in Normal Saline IV
Procedure
Lead sponsor
Regeneris Medical
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Irvine, California • North Attleboro, Massachusetts • Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

NCT04518995
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543 matching placebo, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Bakersfield, California • Encinitas, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jun 11, 2026, 5:09 AM EDT